Table 2.
Top 10 enriched pathways in bladder cancer. Pathway analysis of 143 significantly differentially expressed proteins from bladder cancer was carried out using FunRich.
| No. | Pathway | Number of Proteins from the Dataset |
Proteins from Background Dataset |
p-Value | FDR p-Value |
Altered Proteins from the Dataset |
|---|---|---|---|---|---|---|
| 1 | Immune system | 6 | 522 | 0.009438 | 1 | C3; C1R; C6; C7; NRAS; PVR |
| 2 | Innate immune system | 4 | 183 | 0.00398 | 1 | C3; C1R; C6; C7 |
| 3 | Complement cascade | 4 | 22 | 0.00000095 | 0.001587 | C3; C1R; C6; C7 |
| 4 | Beta3 integrin cell surface interactions | 3 | 43 | 0.000479 | 0.799287 | FGA; LAMA4; PVR |
| 5 | Mesenchymal-to-epithelial transition | 3 | 223 | 0.046173 | 1 | EPS8L2; EPS8L1; S100P |
| 6 | Epithelial-to-mesenchymal transition | 3 | 185 | 0.028762 | 1 | C1R; SERPINF1; MYLK |
| 7 | Signaling by FGFR | 2 | 95 | 0.046495 | 1 | EGFR; NRAS |
| 8 | C-MYB transcription factor network | 2 | 84 | 0.037188 | 1 | NRAS; MPO |
| 9 | Endogenous TLR signaling | 2 | 57 | 0.01807 | 1 | S100A8; S100A9 |
| 10 | Trk receptor signaling mediated by the MAPK pathway | 2 | 34 | 0.006683 | 1 | NRAS; EHD4 |